Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Merck”

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)Recruiting
NCT06841354Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +29 more
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)Recruiting
NCT06863272Phase 1, Phase 2Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Castration-Resistant Prostatic Cancer · Metastasis
United States, Argentina, Australia, Brazil, Canada +14 more
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)Recruiting
NCT06997497Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Colon Adenocarcinoma · Rectal Adenocarcinoma
United States, Argentina, Australia, Brazil, Canada +24 more
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)Recruiting
NCT06717347Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Diffuse Large B-Cell Lymphoma
United States, Argentina, Australia, Belgium, Brazil +30 more
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Recruiting
NCT06393374Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Triple-Negative Breast Cancer
United States, Argentina, Australia, Austria, Belgium +26 more
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)Recruiting
NCT06430801Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Crohn's Disease
United States, Australia, Austria, Belgium, Brazil +42 more
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)Recruiting
NCT06623422Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
United States, Argentina, Australia, Belgium, Brazil +26 more
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)Recruiting
NCT06077760Phase 3Updated Aug 21, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
United States, Argentina, Australia, Belgium, Brazil +28 more
Pembrolizumab in Treating Participants With LeukoplakiaRecruiting
NCT03603223Phase 2Updated Aug 20, 2026
Sponsor: Jonsson Comprehensive Cancer Center
Erythroleukoplakia · Leukoplakia · Verrucous Oral Leukoplakia
United States
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)Recruiting
NCT07187778Phase 2Updated Aug 20, 2026
Sponsor: M.D. Anderson Cancer Center
Clear Cell Renal Cell Carcinoma
United States
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension StudyActive Not Recruiting
NCT05899049Phase 3Updated Aug 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
China
Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent GlioblastomaActive Not Recruiting
NCT04201873Phase 1Updated Aug 20, 2026
Sponsor: Jonsson Comprehensive Cancer Center
Recurrent Glioblastoma
United States
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)Not Yet Recruiting
NCT07776691Phase 3Updated Aug 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Ovarian Cancer · Ovarian Neoplasms · Peritoneal Cancer · Fallopian Tube Cancer
Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator PhenotypeActive Not Recruiting
NCT02658279NAUpdated Aug 20, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Glioma · Recurrent Malignant Glioma
United States
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin LymphomaActive Not Recruiting
NCT05922904Phase 2Updated Aug 20, 2026
Sponsor: M.D. Anderson Cancer Center
Hodgkin Lymphoma
United States
A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044)Not Yet Recruiting
NCT07776665Phase 1Updated Aug 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Healthy
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)Active Not Recruiting
NCT05468697Phase 1, Phase 2Updated Aug 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Renal Cell Carcinoma
United States, Australia, Israel
Mirdametinib + BGB-3245 in Advanced Solid TumorsTerminated
NCT05580770Phase 1, Phase 2Updated Aug 20, 2026
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Advanced Solid Tumor
United States, Australia
Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)Completed
NCT03785964Phase 3Updated Aug 20, 2026
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Desmoid Tumor · Aggressive Fibromatosis
United States, Belgium, Canada, Germany, Italy +2 more
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform NeurofibromasActive Not Recruiting
NCT05101148Phase 1Updated Aug 20, 2026
Sponsor: AstraZeneca
Neurofibromatosis Type 1
United States, Poland, Russia, Spain
ESCUDDO Long Term Follow UpNot Yet Recruiting
NCT07706673N/AUpdated Aug 20, 2026
Sponsor: National Cancer Institute (NCI)
Human Papillomavirus Infection · Human Papillomavirus-Related Malignant Neoplasm
Costa Rica
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]Recruiting
NCT06422143Phase 3Updated Aug 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer · NSCLC
United States, Argentina, Austria, Brazil, Canada +21 more
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)Recruiting
NCT07630974Phase 1, Phase 2Updated Aug 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Malignant Neoplasm
United States, Belgium, Denmark, France, Israel +3 more
A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)Active Not Recruiting
NCT07225959Phase 2Updated Aug 20, 2026
Sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Healthy Participants
United States, United Kingdom
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast CancerActive Not Recruiting
NCT06027268Phase 2Updated Aug 20, 2026
Sponsor: Wake Forest University Health Sciences
Metastatic Triple-Negative Breast Cancer
United States

Previous page Next page